Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Growth Shares
3 quality SaaS ASX shares to buy
⏸️ Investing
Infinite games: 3 ASX shares with long-term visions
⏸️ ASX Shares
2 ASX blue chip shares tipped as buys for 2021
⏸️ ASX Shares
2 blue chip ASX shares to buy next week
⏸️ ASX Shares
2 of the best ASX healthcare shares to buy in 2021
Best Shares
7 top ASX biomedical shares in 2020
Share Market News
Cochlear (ASX:COH) share price edges higher despite losing US patent dispute appeal
⏸️ ASX Shares
2 outstanding blue chip ASX shares to buy in 2021
Share Market News
The two ASX stocks most impacted by the dangerous rise of the Aussie dollar
Share Gainers
2 ASX 200 healthcare shares that outperformed in November
⏸️ ASX Shares
2 ASX blue chip shares tipped as buys
⏸️ ASX Shares
Is the Cochlear (ASX:COH) share price a long term market beater?
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
